Rahway, New Jersey – Merck has announced the acquisition of Cidara Therapeutics (https://www.cidara.com/). According to the company announcement Merck, known as MSD outside of the United States and Canada, is a premier research-intensive biopharmaceutical company with a purpose to use leading-edge science to save and improve lives globally. For over 130 years, the company has been dedicated to developing important medicines and vaccines, bringing hope to humanity. Merck is at the forefront of research, striving to deliver innovative health solutions for the prevention and treatment of diseases in both people and animals. The company fosters a diverse and inclusive global workforce and operates responsibly to enable a safe, sustainable, and healthy future for all. Recently, Merck completed the acquisition of Cidara Therapeutics, strengthening and complementing its expanding respiratory portfolio with the addition of CD388, a potentially first-in-class, long-acting antiviral for influenza prevention.

To learn more about Merck, visit https://www.merck.com/
Company LinkedIn Page: https://www.linkedin.com/company/merck/

Company Contact:

Merck
126 E Scott Ave
Rahway, NJ 7065
908-740-4000

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.